Orexo publishes bond prospectus and applies for listing of its bond loan on NASDAQ OMX Stockholm

Orexo publishes bond prospectus and applies for listing of its bond loan on NASDAQ OMX Stockholm

Uppsala, Sweden – June 9, 2014 – On 30 April 2014, Orexo AB (publ) announced that the company had decided to issue a SEK 500 million bond loan within a total framework amount of SEK 1,000 million on the Swedish bond market. The tenure of the bond is 4 years and it has an annual coupon of STIBOR (3 month) + 4.00 percent.

The company has applied for listing of the bonds on NASDAQ OMX Stockholm. The application has been approved by NASDAQ OMX Stockholm and the first day of trading will be 10 June 2014. In relation to the listing, the company has prepared a prospectus which has been approved by the Swedish Financial Supervisory Authority. The prospectus is available on the company’s website www.orexo.com, and on the website of the Swedish Financial Supervisory Authority www.fi.se.

For further information, please contact:
Henrik Juuel, EVP and CFO Tel: +46 (0)722-20 94 77, E-mail: ir@orexo.com

About Orexo AB
Orexo AB is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. The company is commercializing its proprietary product, Zubsolv® (buprenorphine and naloxone), in the United States for maintenance treatment of opioid dependence. Zubsolv is a novel sublingual formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU, US and Japan. Orexo’s development expertise is within the area of reformulation technologies, and especially sublingual formulations. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.

For information about Orexo, please visit www.orexo.com

Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 5:30 pm CET on June 9, 2014.


About Us

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies.The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.


Documents & Links